Mar 03, 2021 / 07:00PM GMT
Marc Alan Frahm - Cowen and Company, LLC, Research Division - Director
Hello. Welcome back to the Cowen Healthcare Conference. Next session is a fireside chat with Incyte. And we're really pleased to have with us CEO, Herve Hoppenot; CMO, Steven Stein; and CFO, Christiana Stamoulis. We will get to Q&A, and we do encourage the audience to participate. (Operator Instructions)
But we'll start off with -- everybody is going to make a few kind of general overview comments, give a status update, and then we will get into specific questions. So Herve?
Herve Hoppenot - Incyte Corporation - Chairman, President & CEO
Yes. Okay. Thank you, Marc. I'll be very quick. I just will show 2 slides. One is about 2020. So you have it in front of you. And what you can see is basically, it was a year where we had 3 products approved by FDA. So it's Monjuvi, it's Pemazyre, it's Tabrecta. So it was an important year of diversification, and obviously, of growth. The top line, the revenue grew at 24% including milestone, 18% without the milestone. So the sort of run rate
Incyte Corp at Cowen Healthcare Conference (Virtual) Transcript
Mar 04, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers